Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1993 1
1995 1
1996 3
2000 1
2001 1
2002 2
2003 4
2004 7
2005 3
2006 6
2007 6
2008 2
2009 7
2010 12
2011 14
2012 24
2013 26
2014 17
2015 16
2016 11
2017 8
2018 11
2019 5
2020 3
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 20966122

164 results
Results by year
Filters applied: . Clear all
Page 1
FGF-23 as a predictor of renal outcome in diabetic nephropathy.
Titan SM, Zatz R, Graciolli FG, dos Reis LM, Barros RT, Jorgetti V, Moysés RM. Titan SM, et al. Clin J Am Soc Nephrol. 2011 Feb;6(2):241-7. doi: 10.2215/CJN.04250510. Epub 2010 Oct 21. Clin J Am Soc Nephrol. 2011. PMID: 20966122 Free PMC article. Clinical Trial.
Residual proteinuria and eGFR predict progression of renal impairment within 2 years in type 2 diabetic patients with nephropathy who are receiving optimal treatment with angiotensin receptor blockers.
Ivory SE, Packham DK, Reutens AT, Wolfe R, Rohde RD, Lewis J, Atkins RC; Collaborative Study Group. Ivory SE, et al. Nephrology (Carlton). 2013 Jul;18(7):516-24. doi: 10.1111/nep.12053. Nephrology (Carlton). 2013. PMID: 23506627 Clinical Trial.
25 (OH) vitamin D levels and renal disease progression in patients with type 2 diabetic nephropathy and blockade of the renin-angiotensin system.
Fernández-Juárez G, Luño J, Barrio V, de Vinuesa SG, Praga M, Goicoechea M, Lahera V, Casas L, Oliva J; PRONEDI Study Group. Fernández-Juárez G, et al. Clin J Am Soc Nephrol. 2013 Nov;8(11):1870-6. doi: 10.2215/CJN.00910113. Epub 2013 Oct 17. Clin J Am Soc Nephrol. 2013. PMID: 24135218 Free PMC article. Clinical Trial.
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.
de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM. de Zeeuw D, et al. Circulation. 2004 Aug 24;110(8):921-7. doi: 10.1161/01.CIR.0000139860.33974.28. Epub 2004 Aug 9. Circulation. 2004. PMID: 15302780 Clinical Trial.
Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).
Fried LF, Duckworth W, Zhang JH, O'Connor T, Brophy M, Emanuele N, Huang GD, McCullough PA, Palevsky PM, Seliger S, Warren SR, Peduzzi P; VA NEPHRON-D Investigators. Fried LF, et al. Clin J Am Soc Nephrol. 2009 Feb;4(2):361-8. doi: 10.2215/CJN.03350708. Epub 2008 Dec 31. Clin J Am Soc Nephrol. 2009. PMID: 19118120 Free PMC article. Clinical Trial.
FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy.
Lundberg S, Qureshi AR, Olivecrona S, Gunnarsson I, Jacobson SH, Larsson TE. Lundberg S, et al. Clin J Am Soc Nephrol. 2012 May;7(5):727-34. doi: 10.2215/CJN.10331011. Epub 2012 Mar 1. Clin J Am Soc Nephrol. 2012. PMID: 22383747 Free PMC article.
Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, Brenner BM; RENAAL Study Group. Bakris GL, et al. Arch Intern Med. 2003 Jul 14;163(13):1555-65. doi: 10.1001/archinte.163.13.1555. Arch Intern Med. 2003. PMID: 12860578 Clinical Trial.
Dual blockade of the renin-angiotensin-aldosterone system is safe and effective in reducing albuminuria in Asian type 2 diabetic patients with nephropathy.
Tan F, Mukherjee JJ, Lee KO, Lim P, Liew CF. Tan F, et al. Singapore Med J. 2010 Feb;51(2):151-6. Singapore Med J. 2010. PMID: 20358155 Free article. Clinical Trial.
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM. de Zeeuw D, et al. Kidney Int. 2004 Jun;65(6):2309-20. doi: 10.1111/j.1523-1755.2004.00653.x. Kidney Int. 2004. PMID: 15149345 Free article. Clinical Trial.
Low-dose angiotensin II receptor antagonists and angiotensin II-converting enzyme inhibitors alone or in combination for treatment of primary glomerulonephritis.
Renke M, Tylicki L, Rutkowski P, Rutkowski B. Renke M, et al. Scand J Urol Nephrol. 2004;38(5):427-33. doi: 10.1080/00365590410015687. Scand J Urol Nephrol. 2004. PMID: 15764256 Clinical Trial.
164 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback